These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 28158579)

  • 1. First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: subgroup results from the randomized Phase III MERiDiAN trial.
    Masuda N; Takahashi M; Nakagami K; Okumura Y; Nakayama T; Sato N; Kanatani K; Tajima K; Kashiwaba M
    Jpn J Clin Oncol; 2017 May; 47(5):385-392. PubMed ID: 28158579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.
    Miles D; Cameron D; Bondarenko I; Manzyuk L; Alcedo JC; Lopez RI; Im SA; Canon JL; Shparyk Y; Yardley DA; Masuda N; Ro J; Denduluri N; Hubeaux S; Quah C; Bais C; O'Shaughnessy J
    Eur J Cancer; 2017 Jan; 70():146-155. PubMed ID: 27817944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
    Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
    Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
    Aogi K; Masuda N; Ohno S; Oda T; Iwata H; Kashiwaba M; Fujiwara Y; Kamigaki S; Ito Y; Ueno T; Takashima S
    Breast Cancer Res Treat; 2011 Oct; 129(3):829-38. PubMed ID: 21805309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
    J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
    Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
    Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
    Martin M; Roche H; Pinter T; Crown J; Kennedy MJ; Provencher L; Priou F; Eiermann W; Adrover E; Lang I; Ramos M; Latreille J; Jagiełło-Gruszfeld A; Pienkowski T; Alba E; Snyder R; Almel S; Rolski J; Munoz M; Moroose R; Hurvitz S; Baños A; Adewoye H; Hei YJ; Lindsay MA; Rupin M; Cabaribere D; Lemmerick Y; Mackey JR;
    Lancet Oncol; 2011 Apr; 12(4):369-76. PubMed ID: 21429799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
    Rochlitz C; Bigler M; von Moos R; Bernhard J; Matter-Walstra K; Wicki A; Zaman K; Anchisi S; Küng M; Na KJ; Bärtschi D; Borner M; Rordorf T; Rauch D; Müller A; Ruhstaller T; Vetter M; Trojan A; Hasler-Strub U; Cathomas R; Winterhalder R;
    BMC Cancer; 2016 Oct; 16(1):780. PubMed ID: 27724870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
    Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
    Delaloge S; Pérol D; Courtinard C; Brain E; Asselain B; Bachelot T; Debled M; Dieras V; Campone M; Levy C; Jacot W; Lorgis V; Veyret C; Dalenc F; Ferrero JM; Uwer L; Kerbrat P; Goncalves A; Mouret-Reynier MA; Petit T; Jouannaud C; Vanlemmens L; Chenuc G; Guesmia T; Robain M; Cailliot C
    Ann Oncol; 2016 Sep; 27(9):1725-32. PubMed ID: 27436849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study.
    Yamamoto Y; Yamashiro H; Toh U; Kondo N; Nakamura R; Kashiwaba M; Takahashi M; Tsugawa K; Ishikawa T; Nakayama T; Ohtani S; Takano T; Fujisawa T; Toyama T; Kawaguchi H; Mashino K; Tanino Y; Morita S; Toi M; Ohno S
    Breast Cancer; 2021 Jan; 28(1):145-160. PubMed ID: 32715420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
    Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
    Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
    von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
    Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study.
    Schneeweiss A; Förster F; Tesch H; Aktas B; Gluz O; Geberth M; Hertz-Eichenrode MM; Schönegg W; Schumacher C; Kutscheidt A; Kiewitz C; Klawitter S; Schmidt M
    Anticancer Res; 2016 Mar; 36(3):967-74. PubMed ID: 26976985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Brufsky AM; Hurvitz S; Perez E; Swamy R; Valero V; O'Neill V; Rugo HS
    J Clin Oncol; 2011 Nov; 29(32):4286-93. PubMed ID: 21990397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.
    Yardley DA; Bosserman LD; O'Shaughnessy JA; Harwin WN; Morgan SK; Priego VM; Peacock NW; Bass JD; Burris HA; Hainsworth JD
    Breast Cancer Res Treat; 2015 Nov; 154(1):89-97. PubMed ID: 26456573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
    Fang Y; Qu X; Cheng B; Chen Y; Wang Z; Chen F; Xiong B
    Tumour Biol; 2015 Mar; 36(3):1933-41. PubMed ID: 25387808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105).
    Mezzanotte-Sharpe J; ONeill A; Mayer IA; Arteaga CL; Yang XJ; Wagner LI; Cella D; Meropol NJ; Alpaugh RK; Saphner TJ; Swaney RE; Hoelzer KL; Gradishar WJ; Abramson VG; Sundaram PK; Jilani SZ; Perez EA; Lin NU; Jahanzeb M; Wolff AC; Sledge GW; Reid SA
    Breast Cancer Res Treat; 2024 Sep; 207(2):275-282. PubMed ID: 38967884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Kim SB; Dent R; Im SA; Espié M; Blau S; Tan AR; Isakoff SJ; Oliveira M; Saura C; Wongchenko MJ; Kapp AV; Chan WY; Singel SM; Maslyar DJ; Baselga J;
    Lancet Oncol; 2017 Oct; 18(10):1360-1372. PubMed ID: 28800861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.